Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Access & Reimbursement

Set Alert for Market Access & Reimbursement

Latest From Market Access

Busy In-Tray Awaits New EFPIA Boss Nathalie Moll

Nathalie Moll, secretary general of biotech industry body EuropaBio, is to be the next director general of EFPIA, the federation that represents the R&D-based pharmaceutical industry in Europe. With issues such as the forthcoming Brexit negotiations, the EU’s inquiry into medicines access and pricing, and the implementation of the new Clinical Trials Regulation, EFPIA’s new leader will have a lot of weighty dossiers to deal with.

Leadership Regulation

Australia To Make Access To Unauthorized Products Faster And Less Bothersome

New proposals by Australia’s Therapeutic Goods Administration include developing a list of unauthorized drugs that could be made available to patients faster and more easily. A decision to include a product on the list would not be appealable, the TGA says.

Market Access Australia

Alexion Battles UK & France Over Kanuma Price

Alexion is blaming arbitrary pricing systems in Europe for its reimbursement woes with ultra-rare disease drug Kanuma, but one analyst told the Pink Sheet that more creativity is needed from pharma when it comes to pricing orphan therapies.

Pricing Strategies Rare Diseases

MS Patient Treatment Preferences Diverge From Payers, Physicians

Survey finds patient assign greatest value to a drug’s effect on multiple sclerosis symptoms.

Health Technology Assessment Comparative Effectiveness

Value-Based Contracts: Relief From Regulatory Barriers In Sight?

Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.

Pricing Debate US Election 2016

Medicaid Reform And Rebates: State “Opt-Out” Proposed At Hearing

Medicaid rebates have been a fact of life in the pharmaceutical industry for 25 years. But the Affordable Care Act repeal-and-replace debate may open up the possibility of eliminating the mandatory rebates – and the requirement that all drugs be covered by the program.

Government Payers Reimbursement
See All
UsernamePublicRestriction

Register